相关实验视频
Updated: Jul 11, 2025

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.2K
在怀孕期间慢性疹中使用奥马利祖马布的安全性:现实研究
Cataldo Patruno1, Fabrizio Guarneri2, Eustachio Nettis3
1Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Clinical and experimental dermatology
|November 13, 2023
概括
在怀孕期间治疗慢性自发性疹 (CSU) 的 omalizumab 似乎是安全的. 这项研究没有发现孕妇CSU患者与奥马利祖马布治疗的孕妇或胎儿结局的负面影响.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 产科 产科 产科 产科 产科
背景情况:
- 在孕妇中治疗慢性自发性疹症 (CSU) 存在挑战.
- 第二代H1抗组胺剂 (sgAHs) 是怀孕期间常见的CSU治疗方法,但奥马利祖马布的安全性数据有限.
研究的目的:
- 评估奥马利祖马布在怀孕患者中严重的CSU的疗效和安全性.
- 该研究评估了对sgaAH耐药的患者,这些患者怀孕时服用奥马利祖马布或在怀孕期间开始服用它.
主要方法:
- 对29名年龄≥18岁的孕妇进行了回顾性研究.
- 包括在怀孕期间接受奥马利祖马布的妇女或在服用时怀孕的妇女.
主要成果:
- 23名患者在奥马利祖马布治疗中怀孕;6名患者在怀孕期间开始接受治疗.
- 在新生儿中没有观察到任何不良事件,妊娠并发症或先天异常.
- 15名患者在怀孕确认后停止服用奥马利祖马布;8名患者在整个怀孕期间继续服用.
结论:
- 在怀孕前和怀孕期间对CSU治疗Omalizumab没有显示出对母亲或胎儿的不良结果.
- 研究结果表明,奥马利祖马布在怀孕期间严重的CSU中是一种潜在的安全选择.
更多相关视频
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
310
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
310
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
300
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
300
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324
Development of Immunocompetence
317
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
317
Allergic Reactions
27.6K
Overview
27.6K
Rh Blood Group
1.5K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.5K

